Tag Directory / BIOTECH     showing 61–80 of 94


Eikon Therapeutics Raises $381 M in IPO to Advance Live-Cell Imaging in Cancer Drug Discovery / OncoDaily

oncodaily - Eikon Therapeutics has raised $381 million through its IPO, pricing at the top of its range in a strong sign of renewed investor appetite for biotech offerings. The South San […]

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment

Eikon Therapeutics Raises $381 M in IPO to Advance Live-Cell Imaging in Cancer Drug Discovery

5 wks / oncodaily

Eikon Therapeutics Continues the IPO Parade, Raising $381M for Cancer Drug Clinical Trials

5 wks / medcitynews / Frank Vinluan

Saturday, February 7, 2026, 1:21 am / permalink 18871 / 2 stories in 5 wks


Letters, Jan. 27, 2026: ‘A Team Canada must be assembled’ to help diversify trade / Calgary Sun

Jeffrey Morgan / calgarysun - Need to diversify I just watched a video detailing the prior commercial trading practices between Canada and the U.S. It makes me realize there is nothing more important than Canada diversifying its trade with other countries. By ‘nothing,’ I mean all pro…

#healthcare #pharmaceuticals #biotech #drugdevelopment #fda

STS: Assessment of more than one nodal station tied to increased upstaging, survival in NSCLC

5 wks / medicalxpress

Jad Chahoud: Why Timing of Immunochemotherapy Matters in Lung Cancer

5 wks / oncodaily

Giannis Mountzios: What happens to patients with st3 unresectable NSCLC who never receive maintenance IO?

5 wks / oncodaily

Cordyceps sinensis enhances the efficacy of anti-PD-1 immunotherapy in Lewis lung adenocarcinoma

5 wks / nature

Therapeutic potential of targeting MASTL in lung adenocarcinoma

6 wks / nature

First-line Aumolertinib (EGFR tyrosine kinase inhibitor) plus apatinib (VEGFR inhibitor) versus aumolertinib in EGFR-mutant non-small cell lung cancer patients: a randomized, multicenter, phase II trial

6 wks / nature

Narjust Florez: Global Advances and Strategic Priorities in Lung Cancer Care

6 wks / oncodaily

FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutated NSCLC After TKI Therapy

6 wks / oncodaily

Letters, Jan. 27, 2026: ‘A Team Canada must be assembled’ to help diversify trade

6 wks / calgarysun / Jeffrey Morgan

Saturday, January 31, 2026, 2:22 pm / permalink 18622 / 9 stories in 6 wks


FDA lifts hold on one of two Phase 3 gene editing studies by Intellia / Endpoints

Lei Lei Wu / endpoints - The FDA has allowed Intellia Therapeutics to resume one of its two pivotal trials of a gene editing therapy for transthyretin amyloidosis, which is a disease caused by misfolded proteins. Intellia

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #fda

Gene-editing therapy proves effective for Leber's hereditary optic neuropathy

5 wks / medicalxpress

China startup AccurEdit raises $75M for gene editing therapies

5 wks / endpoints / Ryan Cross

FDA lifts hold on one of two Phase 3 gene editing studies by Intellia

6 wks / endpoints / Lei Lei Wu

FDA lifts hold on Intellia’s phase 3 trial for genetic nerve disease

6 wks / beckershospitalreview / Ella Jeffries

Saturday, January 31, 2026, 7:22 am / permalink 18610 / 4 stories in 6 wks


#JPM26: Day 3 at the JP Morgan Healthcare Conference / Endpoints

ENDPOINTS / endpoints - It’s Wednesday at the JP Morgan Healthcare Conference, and as the sessions wind down, we’ll be keeping an eye on presentations from WuXi AppTec and AbbVie. Yesterday afternoon, our Executive Editor Drew Armstrong spoke with ...

#obesity #healthcare #pharmaceuticals #weightloss #biotech #drugdevelopment #digitalhealth

What if Oprah Knew About Fractyl Health?

6 wks / medcitynews / Arundhati Parmar

Which Digital Health Startups Will Win in 2026?

6 wks / medcitynews / Katie Adams

CMS picks Lilly’s Trulicity for third round of Medicare negotiations

6 wks / endpoints / Nicole DeFeudis

The future GLP-1 might be a gene therapy: Report

7 wks / beckershospitalreview / Paige Twenter

Vivek Subbiah: AI-Driven Screening Opens New Era in Drug Discovery

7 wks / oncodaily

David K. Lee: What’s Ahead for Servier in 2026 – Strengthening Our Pipeline, Expanding Our Impact

7 wks / oncodaily

Industry Voices—Micro-app strategy can lead to macro improvements

7 wks / fiercehealthcare

Five Collaboration Trends That Shaped Healthcare AI in 2025

7 wks / medcitynews / Marva Bailer

How Bessemer Sees 2026 Shaping Up as Healthcare AI’s Breakout Year

7 wks / medcitynews / Katie Adams

#JPM26: Hua Medicine plots diabetes drug expansion in China and beyond

7 wks / endpoints / Jared Whitlock

Viewpoint: What Taylor Swift and JPM2026 can teach us about the ‘next era’ of healthcare

7 wks / beckershospitalreview / Mackenzie Bean

Walid Kamoun: Closing J.P. Morgan with Our AI Partnership Expedition

7 wks / oncodaily

Bristol Myers Squibb, Microsoft partner on AI lung cancer detection

7 wks / beckershospitalreview / Ella Jeffries

Bristol Myers Squibb Announces Collaboration with Microsoft to Accelerate the Early Detection of Lung Cancer

7 wks / oncodaily

#JPM26: Regeneron, Lilly, Summit on rivals crowding into same targets

7 wks / endpoints / Andrew Dunn

J&J, Isomorphic sign research deal for AI-made molecules

7 wks / endpoints / Andrew Dunn

GSK makes $2.2B deal for RAPT and its food allergy candidate

7 wks / endpoints / Kyle LaHucik

JPM Deals Recap: Boston Scientific Acquisition, a Mega Round for Parabalis, Enodia Emerges & More

1 month / medcitynews / Frank Vinluan

10 Key MedTech Themes for 2026

1 month / medcitynews / Vinita Kailasanath, Kayla Weston, Yungjee Kim and Shannon O’Hara

Bill Gates: AI Innovations Must Reach the People Who Need Them Most

1 month / oncodaily

Zhaohui Su: Federated Learning With Differential Privacy Balances Accuracy and Patient Data Protection

1 month / oncodaily

Zhaohui Su: AI, Decentralization, and the Evolution of Clinical Trials

1 month / oncodaily

Proud to Have Renee Gala Represent at the 44th J.P. Morgan Healthcare Conference – Jazz Pharmaceuticals

1 month / oncodaily

Zhen Su: Unlocking the Full Potential of Invika as a Next-Generation Immuno-Oncology Backbone

1 month / oncodaily

#JPM26: Day 3 at the JP Morgan Healthcare Conference

2 months / endpoints / ENDPOINTS

#JPM26: Q&A with Bristol Myers Squibb CEO Chris Boerner on 2026 outlook

2 months / endpoints / Andrew Dunn

#JPM26: Novo Nordisk CEO says pharma can learn from the GLP-1 compounding boom

2 months / endpoints / Ngai Yeung

JPM26: Elation Health embeds Anthropic's Claude into EHR to power chart summaries

2 months / fiercehealthcare

Saturday, January 17, 2026, 7:21 pm / permalink 18138 / 28 stories in 1 month


Ancient Wolf Stomach Reveals Remnants of 14,400-Year-Old Woolly Rhino Genome / Discover

discovermagazine - Learn about the woolly rhino genome that was recovered from a wolf's stomach, providing insight on the extinct species' genetic health.

#biotech

Spaghetti-Shaped Parasite in Ancient Canids Reveals the Unusual Origins of Heartworm

7 wks / discovermagazine

One of the last woolly rhinos to walk Earth was eaten by a wolf pup — and scientists have now sequenced its genome from the undigested meat

2 months / livescience

Ancient Wolf Stomach Reveals Remnants of 14,400-Year-Old Woolly Rhino Genome

2 months / discovermagazine

Saturday, January 17, 2026, 1:21 pm / permalink 18133 / 3 stories in 1 month


#JPM26: Day 1 at the JP Morgan Healthcare Conference / Endpoints

ENDPOINTS / endpoints - It’s day 1 at the JP Morgan Healthcare Conference, and the mood heading into the week is one of cautious optimism. Biotech fundraising was off to a hot start in 2026. There ...

#healthcare #pharmaceuticals #biotech #digitalhealth

Nvidia CEO to Lilly CEO: You were running around the forest …

7 wks / medcitynews / Arundhati Parmar

R1 RCM launches prior authorization tool

7 wks / beckershospitalreview / Andrew Cass

AI in Radiotherapy Planning and Workflow Optimization 2026

7 wks / oncodaily

Marty Makary: FDA Priorities for 2026 at JPM26

1 month / oncodaily

JPM26: CommonSpirit CEO teases new divestures, outlines AI wins and pitfalls

2 months / fiercehealthcare

JPM26, Day 1: Waystar rolls out agentic AI; Tempus notches partnerships with Northwestern Medicine, NYU Langone

2 months / fiercehealthcare / , ,

#JPM26: Day 1 at the JP Morgan Healthcare Conference

2 months / endpoints / ENDPOINTS

JPM26: Abridge teams up with Availity to scale real-time prior authorization

2 months / fiercehealthcare

Interpretable inflammation landscape of circulating immune cells

2 months / nature / Laura Jiménez-Gracia

Saturday, January 17, 2026, 8:21 am / permalink 18125 / 9 stories in 1 month


FDA rejects cancer therapy for rare post-transplant disease / Beckers

Ella Jeffries / beckershospitalreview - Atara Biotherapeutics received a second complete response letter from the FDA for its biologics license application for Ebvallo (tabelecleucel). The letter, received Jan. 9, said the FDA no longer considers the single-arm ALLELE trial adequate to support …

#healthcare #pharmaceuticals #publichealth #governmentpolicy #biotech #drugdevelopment #fda

FDA rejects cancer therapy for rare post-transplant disease

2 months / beckershospitalreview / Ella Jeffries

FDA again rejects Atara, Pierre Fabre's cell therapy for Epstein-Barr virus

2 months / endpoints / Max Gelman

Friday, January 16, 2026, 11:55 am / permalink 18057 / 2 stories in 2 months


AI Model Identifies How Every Country Can Improve Its Cancer Outcomes / ESMO

esmo - For the first time, researchers have used machine learning – a type of artificial intelligence (AI) – to identify the most important drivers of cancer survival in nearly all the countries in the world

#healthcare #publichealth #governmentpolicy #biotech


AI Innovations in Cancer

Soha Ahmed Salem: Leading a Powerful AI Collaboration to Improve Cancer Care in LMICs

2 months / oncodaily

AstraZeneca Buys Modella AI: Why Biomarkers, Not Molecules, Are the Real Prize

2 months / oncodaily

Nikhil Vasdev: AI, Imaging, and Genomics Offer Potential to Improve Bladder Cancer Detection and Personalization

2 months / oncodaily

Douglas Flora Discusses AI in Cancer on Chadi Nabhan’s Healthcare Unfiltered

2 months / oncodaily

How AI is transforming health care

2 months / medicalxpress

AI Model Identifies How Every Country Can Improve Its Cancer Outcomes

2 months / esmo

AI model identifies how every country can improve its cancer outcomes

2 months / medicalxpress


Clinical Advances & Trials

Vitamin A may be helping cancer hide from the immune system

2 months / sciencedaily

Suhani: Single Agent ICG vs Dual Dye-Tracer for Sentinel Lymph Node Biopsy in Breast Cancer

2 months / oncodaily

Erdinç Nayır: 3 vs 6 Months of Adjuvant Chemotherapy in Colorectal Cancer

2 months / oncodaily

Vivek Subbiah: Rethinking Cancer of Unknown Primary in the Precision Oncology Era

2 months / oncodaily

Stephanie Haddad: Optimizing Fertility Preservation for AYA Patients – Poster at SCHD26

2 months / oncodaily

Narjust Florez: Community Outreach for EGFR+ Lung Cancer Study in Lawrence

2 months / oncodaily

Stephen V Liu: Results from NRG LU005 Phase III trial

2 months / oncodaily

Thor Halfdanarson: Cabozantinib Shows PFS and ORR Benefit in Grade 3 Neuroendocrine Tumors

2 months / oncodaily

A Combination of Savolitinib and Osimertinib Prolongs PFS in Patients with EGFR-mutated NSCLC and Acquired MET Amplification After Progression On a First-Line EGFR TKI

2 months / esmo


Other Developments

Anirban Maitra: The Most Highly Cited Paper of the Year is Out

2 months / oncodaily


Policy & Advocacy Collaborations

David Collingridge: The Lancet Oncology Collaborates with St Jude for World Cancer Day Webinar

2 months / oncodaily

Tedros Adhanom Ghebreyesus: Cervical Cancer Can Be the First Cancer to Be Eliminated

2 months / oncodaily

Allison Rosen: Advocates Share What Excited Them Most at ASCO GI 2026

2 months / oncodaily

Thomas Hofmarcher: Cancer Dashboard for Serbia Has Been Released

2 months / oncodaily


All Other Stories

AI tool predicts cancer metastasis risk using gene expression signatures

7 wks / medicalxpress

Bristol Myers Squibb and Microsoft Partner to Advance AI-Driven Early Lung Cancer Detection

7 wks / oncodaily

That Cancer Conversation Podcast Season 4: Ep.2 ‘Could AI help us beat cancer?’

7 wks / cancerresearchuk / Cancer Research UK

Spotting skin cancer sooner with the help of AI

7 wks / medicalxpress

Shane O’Hanlon: Managing Multimorbidity in Older People with Cancer

7 wks / oncodaily

Scientists solve a major roadblock holding back cancer cell therapy

7 wks / sciencedaily

Validation of histopathology-based deep learning algorithms for detection of actionable non-small cell lung cancer biomarkers

1 month / nature

George Calin: A Translational Perspective on MicroRNAs in Oncology in the Era of AI

1 month / oncodaily

Hui Huang: Could the ‘g Value’ Transform How We Evaluate Solid Tumor Trials?

1 month / oncodaily

UroFusion-X: a unified multimodal deep learning framework for robust diagnosis, subtyping, and prognosis of urological cancers

1 month / nature

Sabine Brookman-May: Impact of Computational Histology AI Biomarkers on NMIBC Treatment Decisions

1 month / oncodaily

Adrian Lee: Re-imagining Precision Oncology as a Learning System

1 month / oncodaily

Giuseppe Banna: Multimodal Innovation Advances Precision Decision-Making in Bladder Cancer

1 month / oncodaily

Machine learning integrating MRI and clinical features predicts early recurrence of hepatocellular carcinoma after resection

1 month / nature

New Research in Annals of Oncology Shows Machine Learning Revelation of Global Cancer Trend Drivers

1 month / oncodaily

Eliezer Van Allen: Augmenting LLMs with Constantly Evolving Precision Oncology Knowledge

1 month / oncodaily

Leora Horn: Using AI-Driven Digital Biomarkers to Identify the Right Patients

2 months / oncodaily

Thursday, January 15, 2026, 4:21 pm / permalink 17950 / 38 stories in 2 months


Compounding pharmacy sues Eli Lilly, Novo Nordisk over GLP-1 access / Beckers

Ella Jeffries / beckershospitalreview - Strive Compounding Pharmacy filed a federal antitrust lawsuit Jan. 14 against Eli Lilly and Novo Nordisk, alleging the two drugmakers used their market power to restrict access to compounded GLP-1 medications and suppress competition. The lawsuit, filed i…

#obesity #healthcare #pharmaceuticals #drugpricing #elililly #novonordisk #weightloss #publichealth #biotech

Stephen Liu: What GLP-1 Therapies May Mean for Cancer Risk

7 wks / oncodaily

#JPM26: Sandoz CEO on Ozempic generic launch plans for 2026

2 months / endpoints / Andrew Dunn

A compounding pharmacy hits back at Eli Lilly, Novo Nordisk with antitrust lawsuit

2 months / endpoints / Shelby Livingston

Compounding pharmacy sues Eli Lilly, Novo Nordisk over GLP-1 access

2 months / beckershospitalreview / Ella Jeffries

Thursday, January 15, 2026, 1:23 pm / permalink 17926 / 4 stories in 2 months


NVIDIA and Eli Lilly Launch $1B AI Co-Innovation Lab to Reinvent Drug Discovery / OncoDaily

oncodaily - Dave Ricks, Chair, CEO at Eli Lilly and Company, shared Eli Lilly and Company‘s post on LinkedIn, adding: “Exciting news from the JPMorgan Healthcare Conference: Lilly and NVIDIA are joining […]

#healthcare #pharmaceuticals #elililly #publichealth #biotech #drugdevelopment

NVIDIA and Eli Lilly Launch $1B AI Co-Innovation Lab to Reinvent Drug Discovery

2 months / oncodaily

Eli Lilly, Nvidia sign five-year, up to $1B deal for AI laboratory

2 months / endpoints / Andrew Dunn

Thursday, January 15, 2026, 1:23 pm / permalink 17925 / 2 stories in 2 months


Merck Could Strike 30 Billion Deal for Revolution Medicines / OncoDaily

oncodaily - According to the Financial Times, Merck is in talks to acquire Revolution Medicines, a Redwood City, California-based cancer drug developer, in a deal that could value the company at roughly […]

#healthcare #pharmaceuticals #publichealth #biotech #mergersandacquisitions #corporatetakeover #drugdevelopment

Merck Could Strike 30 Billion Deal for Revolution Medicines

2 months / oncodaily

Speculation builds about a deal for Revolution Medicines

2 months / endpoints / Kyle LaHucik

Monday, January 12, 2026, 1:21 am / permalink 17767 / 2 stories in 2 months


Aktis Has First Biotech IPO of 2026, Raising $318M to Expand the Reach of Radiopharmaceuticals / MedCity

Frank Vinluan / medcitynews - Aktis Oncology’s IPO will support a pipeline of “miniprotein” radioconjugates that could offer advantages over other targeted radiation cancer treatments. In addition to its internal pipeline, Aktis has a discovery partnership with Eli Lilly. The post Akt…

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment

Novartis licenses radiopharma asset from Chinese biotech for $50M upfront

2 months / endpoints / Ayisha Sharma

Introducing the ESGO 2026 Social Media Ambassador Team

2 months / oncodaily

Kimryn Rathmell Welcomes Alex Bates as the New Director of Executive Communications for OSUCCC – James

2 months / oncodaily

Providing Essential Medicines for Children With Cancer in El Salvador – ACT 4 Children

2 months / oncodaily

Dean Crowe: Why Decisions about Infectious Diseases Policy Shouldn’t Slow mRNA Cancer Research

2 months / oncodaily

Developing National Cancer Control Plans in LMICs – NCI Center for Global Health

2 months / oncodaily

Aktis' 25% IPO bounce builds hope for 2026's public offerings

2 months / endpoints / Kyle LaHucik

Aktis Has First Biotech IPO of 2026, Raising $318M to Expand the Reach of Radiopharmaceuticals

2 months / medcitynews / Frank Vinluan

Saturday, January 10, 2026, 10:21 am / permalink 17733 / 8 stories in 2 months


FDA rejects Corcept’s cortisol-targeting drug for Cushing’s syndrome / Endpoints

Ayisha Sharma / endpoints - Corcept Therapeutics failed to secure US approval for its drug candidate as a hormonal disorder treatment. The FDA rejected Corcept’s selective cortisol modulator relacorilant for Cushing’s syndrome, according to a company

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #fda

FDA rejects cortisol modulator for hypertension

2 months / beckershospitalreview / Ella Jeffries

FDA rejects Corcept’s cortisol-targeting drug for Cushing’s syndrome

2 months / endpoints / Ayisha Sharma

Monday, January 5, 2026, 1:21 am / permalink 17484 / 2 stories in 2 months


Low-dose peanut therapy shown to protect children with peanut allergies / Medical Express

medicalxpress - Children with peanut allergies may not need large doses of peanut oral immunotherapy (OIT) to build protection against peanuts, finds a new study led by The Hospital for Sick Children (SickKids) and Montreal Children's Hospital.

#healthcare #publichealth #biotech #drugdevelopment

Woman hospitalised over dessert containing nuts

2 months / bbc

Lower Doses of Peanut Immunotherapy Could Make Allergy Treatment More Accessible

2 months / discovermagazine

Low-dose peanut therapy shown to protect children with peanut allergies

2 months / medicalxpress

Saturday, January 3, 2026, 5:21 pm / permalink 17464 / 3 stories in 2 months


Intratumoral Bacterial Burden Drives Immunotherapy Resistance in Head and Neck Cancer / OncoDaily

oncodaily - Immune checkpoint blockade (ICB) benefits only a subset of patients with head and neck squamous cell carcinoma (HNSCC), and commonly used biomarkers (PD-L1, TMB) remain imperfect in this setting. This […]

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment

Nivolumab Added to Cisplatin and Radiotherapy Improves DFS in Patients with High-Risk Resected Locally Advanced SCCHN

2 months / esmo

NIVOPOST-OP Trial: Postoperative Nivolumab Plus Cisplatin-Based Chemoradiotherapy in High-Risk Locally Advanced Head and Neck Squamous Cell Carcinoma

2 months / oncodaily

Harnessing the microbiome for cancer therapy

2 months / nature

David Sher: 2 Nature Cancer Papers on Tumor Bacterial Burden and Immunotherapy Response

2 months / oncodaily

Global Incidence of Lip, Oral Cavity, and Pharyngeal Cancers – American Cancer Society Journals

2 months / oncodaily

Intratumoral Bacterial Burden Drives Immunotherapy Resistance in Head and Neck Cancer

2 months / oncodaily

Tumor bacteria linked to immunotherapy resistance in head and neck cancer

2 months / medicalxpress

Saturday, January 3, 2026, 11:20 am / permalink 17458 / 7 stories in 2 months


AstraZeneca bets up to $2B on Jacobio’s pan-KRAS inhibitor for cancer / Endpoints

Ayisha Sharma / endpoints - AstraZeneca is spending $100 million upfront to secure ex-China rights for an early-stage cancer drug developed by Jacobio Pharma. The UK drugmaker will be responsible for advancing and selling the oral pan-KRAS inhibitor, JAB-23E73, in ...

#pharmaceuticals #biotech #mergersandacquisitions #drugdevelopment

Nelson Dusetti: Why Oncogenic KRAS Alone Is Not Sufficient to Drive Pancreatic Cancer?

2 months / oncodaily

BridgeBio shares KRAS data; Hutchmed's Phase 3 success in China

2 months / endpoints / ENDPOINTS

Autologous multiantigen-targeted T cell therapy for pancreatic cancer: a phase 1/2 trial

2 months / nature / Benjamin L. Musher

Verastem axes Phase 1/2 lung cancer trial of Avmapki, pivots to KRAS blocker

2 months / endpoints / Ayisha Sharma

Naoto T. Ueno: Breakthrough Advances in K-RAS Inhibitor Development

2 months / oncodaily

Jacobio Pharma and AstraZeneca Strike $2 B Deal for Pan‑KRAS Inhibitor

2 months / oncodaily

AstraZeneca bets up to $2B on Jacobio’s pan-KRAS inhibitor for cancer

2 months / endpoints / Ayisha Sharma

Saturday, December 27, 2025, 6:20 am / permalink 17306 / 7 stories in 2 months


Sanofi buys hepatitis B vaccine maker Dynavax for $2.2B; gets CRL for MS drug / Endpoints

Elizabeth Cairns / endpoints - Sanofi is set to supplement its vaccine offering with the acquisition of Dynavax Technologies for $2.2 billion in cash, the companies said Wednesday. Separately, Sanofi said the ...

#healthcare #pharmaceuticals #publichealth #biotech #mergersandacquisitions #corporatetakeover #drugdevelopment #vaccinesafety

A One Health trial design to accelerate Lassa fever vaccines

2 months / nature / David Simons

Sanofi’s Vaccine Lineup Gets a Shot in the Arm With $2.2B Dynavax Acquisition

2 months / medcitynews / Frank Vinluan

Sanofi buys hepatitis B vaccine maker Dynavax for $2.2B; gets CRL for MS drug

2 months / endpoints / Elizabeth Cairns

Saturday, December 27, 2025, 2:21 am / permalink 17302 / 3 stories in 2 months


FDA Approved Rucaparib for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer / OncoDaily

oncodaily - On December 17, 2025, the FDA issued a regular approval for rucaparib (Rubraca®), marking the formal conversion of its earlier accelerated authorization into full approval for BRCA-mutated metastatic castration-resistant prostate […]

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #fda

Sumanta K. Pal: Beautiful Articulation of How We Can Personalize Therapy for Advanced Prostate Cancer

2 months / oncodaily

NanoKnife Success Rate for Prostate Cancer. What Patients Need to Know in 2026

2 months / oncodaily

Neal Shore: Efficacy and Safety of Treatments for Metastatic Castration-Sensitive Prostate Cancer

2 months / oncodaily

How testosterone went from prostate cancer villain to potential ally

2 months / medicalxpress

Pasritamig (JNJ-78278343): A Patient Guide To A New Immunotherapy For Advanced Prostate Cancer

2 months / oncodaily

Pasritamig (JNJ-78278343): A Next-Generation T-Cell Engager for Metastatic Castration-Resistant Prostate Cancer

2 months / oncodaily

AMPLITUDE Trial: Niraparib Plus Abiraterone in HRR-Mutated mCSPC

2 months / oncodaily

Prostate cancer diagnosis using sensitive and sophisticated machine learning classifiers based on non-invasive urinary RNA biomarkers (PCASSO)

2 months / nature

Accelerated cancer drug approvals yield modest survival gains at significant Medicare cost

2 months / medicalxpress

Liang Cheng: Great Honor to Have Contributed 3 Articles to the Special Issue in Urologic Oncology

2 months / oncodaily

Axel S. Merseburger: Insights on ARLDDs and the rechARge Study for mCRPC

2 months / oncodaily

FDA approves prostate cancer drug

2 months / beckershospitalreview / Ella Jeffries

FDA Approved Rucaparib for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer

2 months / oncodaily

Saturday, December 20, 2025, 9:20 pm / permalink 17185 / 13 stories in 2 months


Carolyn Bertozzi Returns to Eli Lilly and Company Board of Directors 2025 / OncoDaily

oncodaily - Eli Lilly and Company has announced the election of Carolyn R. Bertozzi, Ph.D., as a returning member of its Board of Directors, effective December 8, 2025. In her renewed role, […]

#healthcare #pharmaceuticals #elililly #biotech #drugdevelopment

How to watch one of the year's best meteor showers, the Geminids

3 months / go

Carolyn Bertozzi Returns to Eli Lilly and Company Board of Directors 2025

3 months / oncodaily

Monday, December 15, 2025, 4:22 am / permalink 16960 / 2 stories in 3 months


FDA approves 1st gene therapy for Wiskott-Aldrich syndrome / Beckers

Ella Jeffries / beckershospitalreview - The FDA has approved Waskyra (etuvetidigene autotemcel), the first gene therapy for Wiskott-Aldrich syndrome, a rare and life-threatening immune disorder. Waskyra is indicated for pediatric patients 6 months and older, as well as adults with Wiskott-Aldri…

#healthcare #pharmaceuticals #publichealth #biotech #drugdevelopment #fda

Anastasia Conti: Excited to Speak at CRISPRMED26 in Copenhagen

3 months / oncodaily

Western genetic medicine makers turn to Chinese investigator-initiated trials

3 months / endpoints / Ryan Cross

FDA Flexibility Leads to First Approved Gene Therapy for Rare Blood & Immune System Disorder

3 months / medcitynews / Frank Vinluan

FDA approves 1st gene therapy for Wiskott-Aldrich syndrome

3 months / beckershospitalreview / Ella Jeffries

Monday, December 15, 2025, 2:21 am / permalink 16954 / 4 stories in 3 months


Back to Top


BIOTECH Heatmap

90 days, weeks are vertical, left is older; hover for info, click to see that day's coverage.



More Top Stories...

FDA refuses to review Moderna mRNA flu vaccine application

Moderna’s mRNA flu vaccine application has been rejected by the FDA—Moderna received a refusal‐to‐file letter while accusing the agency of shifting its review standards. Multiple reports echo this regulatory setback, fueling industry concerns over consistent, transparent decision‐making. More...


FDA CRL halts AstraZeneca’s Saphnelo prefilled pen approval

AstraZeneca’s application to market its subcutaneous prefilled pen formulation of Saphnelo for treating lupus has hit a roadblock after the FDA issued a complete response letter. The decision delays the drug’s approval and raises questions about its future in the competitive immunotherapy market. More...


CMS proposes sweeping changes to ACA marketplace plan rules

CMS has proposed a major rule reshaping Affordable Care Act marketplace policies, including loosening limits on non-standard plan designs and promoting lower-premium options such as catastrophic coverage. The agency says the changes will reduce costs and boost flexibility, while critics warn they could increase confusion and weaken consumer protections—because shopping for insurance clearly wasn’t complicated enough. More...


Tenet forecasts major ACA exchange enrollment drop and financial hit

Tenet Healthcare is warning that the expiration of enhanced Affordable Care Act premium tax credits will drive a steep reduction in ACA exchange enrollment, projecting a significant revenue impact in 2026. Despite the headwind, the company says it expects earnings growth, leaning on acuity and operational performance—because nothing calms Wall Street like “we’ll make it up somewhere else.” More...


City of Hope promotes Nisha Morris to senior marketing chief

City of Hope named Nisha Morris as Senior Vice President and Chief Marketing and Communications Officer, adding marketing leadership to its executive team. The move signals a renewed focus on brand, outreach, and patient engagement as the cancer center sharpens its communication and growth strategies. More...


NorthFeed Inc.

Disclaimer: The information provided on this website is intended for general informational purposes only. While we strive for accuracy, we do not guarantee the completeness or reliability of the content. Users are encouraged to verify all details independently. We accept no liability for errors, omissions, or any decisions made based on this information.